Endothelial dysfunction in patients with systemic lupus erythematosus


Cite item

Full Text

Abstract

It is currently shown that endothelial function study is a rather informative way of assessing the cardiovascular risk. Many investigations have shown the high rate of endothelial dysfunction (ED) in systemic lupus erythematosus (SLE); however, clinical data on ED in patients with SLE are scarce; which seems to be generated by difficulties in the diagnosis of this condition and to necessitate the modification of the existing diagnostic methods. The signs of ED were detected in 40% of the patients. Its development was associated with the activity of SLE, the presence of Raynaud's syndrome, elevated systolic blood pressure, plasma fibrinogen levels, and the larger daily dose of prednisolone. The method proposed by the authors to study endothelial function from the diagnostic capacities on the basis of volumetric compression oscillometry is comparable with the standard ultrasound method, which allows its clinical use to evaluate the endothelial state.

References

  1. Cooke J. P., Tsao P. S. Is NO an endogenous antiatherogenic molecule? Arterioscler. Thromb. 1994; 14: 753-759.
  2. Libby P. Current concepts of the pathogenesis of the acute coronary syndrome. Circulation 2001; 104: 365-372.
  3. Mehra V. C., Ramgolam V. S., Bender J. R. et al. Cytokines and cardiovascular disease. J. Leukoc. Biol. 2005; 78: 805- 818.
  4. Thurberg B., Collins T. The nuclear factor-kappa B/inhibitor of kappa В autoregulatory system and atherosclerosis. Curr. Opin. Lipidol. 1998; 9: 387-396.
  5. Vane J. R., Anggard Е. Е., Botting R. M. Regulatory functions of the vascular endothelium. N. Engl. J. Med. 1990; 323: 27- 36.
  6. Jones C. J. H., Kuo L., Davis M. J. et al. Role of nitric oxide in coronary microvascular responses to adenosine and increased metabolic demand. Circulation 1996; 91: 1807-1813.
  7. Loscalzo J., Welch G. Nitric oxide and its role in the cardiovascular system. Progr. Cardiovasc. Dis. 1995; 38: 87-104.
  8. Du X., Stocklauser-Farber K., Rosen P. Generation of reactive oxygen intermediates, activation of NF-κВ, and in human endothelial cells by glucose: role of nitric oxide synthase? Free Radic. Biol. Med. 1999; 27: 752-763.
  9. Johnston C. J. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J. Cardiovasc. Pharmacol. 1992; 20: S1-S5.
  10. Петрищев Н. Н., Власов Т. Д. Физиология и патофизиология эндотелия. В кн.: Петрищев Н. Н., ред. Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция. СПб.: Изд-во СПбГМУ; 2003. 4-38.
  11. Rubanyi G. M. The role of endothelium in cardiovascular homeostasis and diseases. J. Cardiovasc. Pharmacol. 1993; 22: S1-S14.
  12. Vanhoutte P. M. How to assess endothelial function in human blood vessels. J. Hypertens. 1999; 17: 1047-1058.
  13. Benjamin E. J., Larson M. G., Kupka M. J. et al. Cross-sectional correlates of brachial artery endothelial function in the community: The NHBL'S Framingham Heart Study. Circulation 2001; 104: 11-152.
  14. Pederson S. D., Pederson E. M., Ringgard S., Falk E. Coronary artery disease: plaque vulnerability, disruption, and thrombosis. In: Fuster V., ed. The vulnerable atherosclerotic plaque. New York: Futura Publishing Co; 1999. 1-24.
  15. Sica D. Endothelial cell function. New considerations. Eur. Heart. J. 2000; 21: B13-B21.
  16. Cooke J. P., Tsao P. S. Go with the flow. Circulation 2001; 103: 2773-2775.
  17. Traub O., Berk В. С. Laminar shear stress. Mechanism by which endothelial cells transducer an atheroprotective force. Arterioscler. Thromb. Vasc. Biol. 1998; 18: 677-685.
  18. Miura H., Watchel R. E., Liu Y. et al. Flow-induced dilation of human coronary arterioles: important role of Ca(2+)-activated K(+) channels. Circulation 2001; 103: 1992-1998.
  19. Sorensen K. E., Kristensen I. B., Celermajer D. S. Atherosclerosis in the human brachial artery. J. Am. Coll. Cardiol. 1997; 29 (2): 318-352.
  20. Celermajer D. S., Sorensen K. E., Gooch V. M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340 (8828): 1111-1115.
  21. Затейщиков Д. А., Минушкина Л. О., Кудряшова О. Ю. и др. Функциональное состояние эндотелия у больных артериальной гипертонией и ИБС. Кардиология 2000; 6: 14-17.
  22. Иванова О. В., Рогоза А. Н., Балахонова Т. В. и др. Определение чувствительности плечевой артерии к напряжению сдвига на эндотелии как метод оценки состояния эндотелийзависимой вазодилатации с помощью ультразвука высокого разрешения у больных с артериальной гипертензией. Кардиология 1998; 3: 37-41.
  23. Schachinger V., Britten M. B., Zeiher A. M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101 (16): 1899-1906.
  24. Schroeder S., Enderle M. D., Ossen R. et al. Noninvasive determination of the endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging. Am. Heart J. 1999; 138: 731-739.
  25. Yataco R., Corretti M., Gardner A. W. et al. Endothelial reactivity an cardiac risk factors in older patients with peripheral arterial disease. Am. J. Cardiol. 1999; 83: 754-758.
  26. Berliner J. A., Navab M., Fogelman A. M. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation 1995; 91: 2488-2496.
  27. Shoji Т., Nishizawa J., Fukumoto M., Shimamura K. Inverse relationship between circulating oxidized low density lipoprotein and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000; 148: 171-177.
  28. Siow R. C. M., Redley K. C., Richards J. P. et al. Vitamin С protects human vascular smooth muscle cells against apoptosis induced by moderately oxidized LDL containing high levels of lipid hydroperoxides. Arterioscler. Thomb. Vasc. Biol. 1999; 19: 2387-2394.
  29. Perticone F., Maio R., Tripepi G., Zoccali С. Endothelial dysfunction and mild renal insufficiency in essential hypertension. Circulation 2004; 110: 821-825.
  30. Stam F., van Guldener C., Becker A. et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn Study. J. Am. Soc. Nephrol. 2006; 17: 537-545.
  31. Landray M. J., Wheeler D. C., Lip G. Y. et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am. J. Kidney Dis. 2004; 43 (2): 244-253.
  32. El-Magadmi M., Bodill H., Ahmad Y. et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004; 110 (4): 399-404.
  33. Karadag O., Calguneri M., Atalar E. et al. Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Clin. Rheumatol. 2007; 26(5): 695-699.
  34. Kiss E., Soltesz P., Der H. et al. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J. Autoimmun. 2006; 27 (4): 211-217.
  35. Lima D. S., Sato E. I., Lima V. C. et al. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J. Rheumatol. 2002; 29 (2): 292-297.
  36. Tani C., Mosca M., d'Ascanio A. et al. Chronic inflammation and endothelial dysfunction: analysis of a cohort of patients with SLE and UCTD. Reumatismo 2006; 58 (3): 212-218.
  37. Turner E., Dishy V., Chung C. P. et al. Endothelial function in systemic lupus erythematosus: relationship to disease activity, cardiovascular risk factors, corticosteroid therapy, and coronary calcification. Vasc. Hlth Risk Manag. 2005; 1 (4): 357- 360.
  38. Frijns R., Fijnheer R., Schiel A. et al. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers. J. Rheumatol. 2001; 28: 514-519.
  39. Бобкова И. Н. Прокоагулятная и фибринолитическая активность сосудистого эндотелия у больных волчаночным нефритом: Автореф. дис. ... канд. мед. наук. М.; 1996.
  40. Oates J. C., Shaftman S. R., Self S. E., Gilkeson G. S. Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. Arthr. and Rheum. 2008; 58: 263-272.
  41. Bultink I. E., Teerlink T., Heijst J. A. et al. Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity, and organ damage in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2005; 64 (9): 1362-1365.
  42. Kielstein J. T., Zoccali G. Asymmetric dimethylarginine (ADMA): a cardiovascular risk factor and a uremic toxin coming of age? Am. J. Kidney Dis. 2005; 46: 186-202.
  43. Zoccali С. Asymmetric dimethylarginine (ADMA): a cardiovascular risk factor on the move. J. Hypertens. 2006; 24: 611- 619.
  44. Clancy R., Marder G., Martin V. et al. Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse. Arthr. and Rheum. 2001; 44: 1203-1208.
  45. Clancy R. M. Circulating endothelial cells and vascular injury in systemic lupus erythematosus. Curr. Rheumatol. Rep. 2000; 2: 39-43.
  46. Renaudineau Y., Dugue C., Dueymes M., Youinou P. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmune Rev. 2002; 1: 365-372.
  47. Насонов Е. Л., Алекберова З. C., Саложин К. В. и др. Антиэндотелиальные антитела при системной красной волчанке у мужчин: связь с поражением почек и антифосфолипидным синдромом. Тер. арх. 1996; 6: 36-49.
  48. Tanaseanu C. M., Tanaseanu S., Moldoveanu E., Dumitrascu A. Endothelial dysfunction in patients with Systemic Lupus Erythematosus. Lupus 2008; 17 (5): 470.
  49. Zweig M. H., Campbell G. ROC Plots: A fundamental evaluation tool in clinical medicine. Clin. chem. 1993; 39 (4): 561- 577.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies